Jacques Gardette

About Jacques Gardette

Jacques Gardette is the founder of BIOCORP, a French industrial company specializing in the development and manufacturing of medical devices and drug delivery systems. Based in Issoire, near Clermont-Ferrand, the company was created in 2004 and grew by combining industrial manufacturing, intellectual property, and medical innovation. From the outset, Gardette promoted an entrepreneurial model built on keeping production in France, developing proprietary technologies, and serving major pharmaceutical groups with specialized solutions. At BIOCORP, Jacques Gardette served as founder, Chief Executive Officer, and later Chairman of the Board. He oversaw the company’s transformation from a regional industrial business into a listed company, with BIOCORP joining Euronext Growth Paris in 2015. Under his leadership, the group strengthened its research and development capabilities and expanded its portfolio of innovative products, particularly in connected devices for diabetes care. The company’s strategy combined recurring revenues from industrial manufacturing with value creation through licensing and technology partnerships. Gardette’s leadership style was marked by a strong focus on industrial innovation, production quality, and commercial execution. BIOCORP became known for products such as DataPen, described as an early connected insulin injector that supported better treatment adherence and digital monitoring of injections. This technological direction helped establish BIOCORP as a recognized player in connected medical devices. In 2023, BIOCORP joined the Novo Nordisk group following a controlling acquisition. At that time, Jacques Gardette resigned from his mandates as director and Chairman of the Board, closing nearly two decades of leadership at the company. His career reflects the profile of a founder-operator who built an industrial SME, took it public, and ultimately guided it into a strategic partnership with a global healthcare leader.